FDG PET CT Brain Plain (FDG Isotope Charges Extra) is an advanced functional imaging test that evaluates glucose metabolism in different regions of the brain using a radioactive tracer called Fluorodeoxyglucose (FDG). It is performed to identify abnormal patterns of brain activity associated with Alzheimer's disease and other dementias, helping clinicians assess cognitive impairment, differentiate between various neurodegenerative disorders, and support early diagnosis and appropriate treatment planning.
In Alzheimer’s disease, certain brain regions show reduced glucose metabolism. FDG PET CT can identify these characteristic patterns, helping doctors distinguish Alzheimer’s disease from normal aging and other types of dementia when interpreted with clinical findings.
Yes, FDG PET CT may detect abnormal brain metabolism before significant structural changes become visible on routine imaging. Early detection can help support timely diagnosis, treatment planning, and appropriate management of cognitive decline.
No. MRI provides detailed images of brain structure, while FDG PET CT evaluates brain function and glucose metabolism. These tests provide complementary information and are often used together during the evaluation of dementia and cognitive disorders.
This scan may be recommended for individuals with unexplained memory loss, progressive cognitive decline, behavioral changes, suspected Alzheimer’s disease, or when doctors need to differentiate between different forms of dementia and other neurological disorders.
The scan can help evaluate other dementias, frontotemporal dementia, Lewy body dementia, epilepsy, certain brain tumors, movement disorders, and other neurological conditions that affect brain metabolism and function.